Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

Association between a functional insertion/deletion polymorphism in IL1A gene and risk of papillary thyroid carcinoma

Authors: Linbo Gao, Xinxin Zhu, Zhihui Li, Lijuan Li, Tao Wang, Huaizhong Hu, Wanli Guo, Peng Chen, Jingqiang Zhu, Lin Zhang

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

The aim of this study was to evaluate whether an insertion/deletion polymorphism (rs3783553) locating in the miR-122 target gene IL1A 3′ untranslated region was related to the risk of papillary thyroid carcinoma (PTC). Genomic DNA was extracted from peripheral venous blood of 273 patients with PTC and 509 controls. The IL1A rs3783553 polymorphism was genotyped by using a polymerase chain reaction assay. No significant difference of the distribution of the IL1A rs3783553 polymorphism was observed between PTC patients and controls. However, patients carrying the IL1A rs3783553 ins/ins genotype and ins allele had significantly decreased risks for developing T3 and T4 when compared with patients carrying the IL1A rs3783553 del/del genotype and del allele (ins/ins vs. del/del: OR = 0.22, 95 % confidence interval (CI), 0.09–0.54; ins vs. del: OR = 0.58, 95 % CI, 0.41–0.83, respectively). These results suggest that the rs3783553 polymorphism may be used as a genetic marker to predict the size/extension of PTC.
Literature
1.
2.
Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115(16):3801–7.PubMedCrossRef
3.
Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164–7.PubMedCrossRef
4.
Sakorafas GH, Giotakis J, Stafyla V. Papillary thyroid microcarcinoma: a surgical perspective. Cancer Treat Rev. 2005;31(6):423–38.PubMedCrossRef
5.
6.
Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, et al. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3′ untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis. 2009;30(12):2064–9.PubMedCrossRef
7.
Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008;105(20):7269–74.PubMedCentralPubMedCrossRef
8.
Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008;68(20):8535–40.PubMedCentralPubMedCrossRef
9.
Landi D, Moreno V, Guino E, Vodicka P, Pardini B, Naccarati A, et al. Polymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with colorectal cancer. Mutat Res. 2011;717(1–2):109–15.PubMedCrossRef
10.
Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis. 2008;29(3):579–84.PubMedCrossRef
11.
Li ZH, Pan X, Han BW, Guo XM, Zhang Z, Jia J, et al. A let-7 binding site polymorphism rs712 in the KRAS 3′ UTR is associated with an increased risk of gastric cancer. Tumour Biol. 2013;34(5):3159–63.
12.
Yang ZH, Dai Q, Zhong L, Zhang X, Guo QX, Li SN. Association of IL-1 polymorphisms and IL-1 serum levels with susceptibility to nasopharyngeal carcinoma. Mol Carcinog. 2011;50(3):208–14.PubMedCrossRef
13.
Zeng XF, Li J, Li SB. A functional polymorphism in IL-1A gene is associated with a reduced risk of gastric cancer. Tumour Biol. 2013;35(1):265–268
14.
Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.PubMedCrossRef
15.
Jazdzewski K, Liyanarachchi S, Swierniak M, Pachucki J, Ringel MD, Jarzab B, et al. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A. 2009;106(5):1502–5.PubMedCentralPubMedCrossRef
16.
Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol. 2008;82(16):8215–23.PubMedCentralPubMedCrossRef
17.
Reddi HV, Madde P, Milosevic D, Hackbarth JS, Algeciras-Schimnich A, McIver B, et al. The putative PAX8/PPARgamma fusion oncoprotein exhibits partial tumor suppressor activity through up-regulation of micro-RNA-122 and dominant-negative PPARgamma activity. Genes Cancer. 2011;2(1):46–55.PubMedCentralPubMedCrossRef
18.
Reddi HV, Driscoll CB, Madde P, Milosevic D, Hurley RM, McDonough SJ, et al. Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARgamma fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy. Cancer Gene Ther. 2013;20(5):267–75.PubMedCrossRef
19.
20.
Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605–21.PubMedCrossRef
21.
Apte RN, Voronov E. Is interleukin-1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? Immunol Rev. 2008;222(1):222–41.PubMedCrossRef
22.
Kimura H, Yamashita S, Namba H, Tominaga T, Tsuruta M, Yokoyama N, et al. Interleukin-1 inhibits human thyroid carcinoma cell growth. J Clin Endocrinol Metab. 1992;75(2):596–602.PubMed
23.
Kammoun-Krichen M, Bougacha-Elleuch N, Mnif M, Bougacha F, Charffedine I, Rebuffat S, et al. IL-1beta a potential factor for discriminating between thyroid carcinoma and atrophic thyroiditis. Eur Cytokine Netw. 2012;23(3):101–6.PubMed
24.
Zeki K, Nakano Y, Inokuchi N, Watanabe K, Morimoto I, Yamashita U, et al. Autocrine stimulation of interleukin-1 in the growth of human thyroid carcinoma cell line NIM 1. J Clin Endocrinol Metab. 1993;76(1):127–33.PubMed
25.
Zeki K, Morimoto I, Arao T, Eto S, Yamashita U. Interleukin-1alpha regulates G1 cell cycle progression and arrest in thyroid carcinoma cell lines NIM1 and NPA. J Endocrinol. 1999;160(1):67–73.PubMedCrossRef
26.
Inokuchi N, Zeki K, Morimoto I, Nakano Y, Fujihira T, Yamashita U, et al. Stimulatory effect of interleukin-1 alpha on proliferation through a Ca2+/calmodulin-dependent pathway of a human thyroid carcinoma cell line, NIM 1. Jpn J Cancer Res. 1995;86(7):670–6.PubMedCrossRef
27.
Zhang HT. Int7G24A variant of the TGFBR1 gene and cancer risk: a meta-analysis of three case-control studies. Lung Cancer. 2005;49(3):419–20.PubMedCrossRef
28.
Lu D, Chen L, Shi X, Zhang X, Ling X, Chen X, et al. A functional polymorphism in interleukin-1alpha (IL1A) gene is associated with risk of alopecia areata in Chinese populations. Gene. 2013;521(2):282–6.PubMedCrossRef
Metadata
Title
Association between a functional insertion/deletion polymorphism in IL1A gene and risk of papillary thyroid carcinoma
Authors
Linbo Gao
Xinxin Zhu
Zhihui Li
Lijuan Li
Tao Wang
Huaizhong Hu
Wanli Guo
Peng Chen
Jingqiang Zhu
Lin Zhang
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1512-6

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

Clinical significance of S100A2 expression in gastric cancer

Research Article

The association of APE1 Asp148Glu gene polymorphisms and lung cancer risk: an updated meta-analysis

Research Article

Axl gene knockdown inhibits the metastasis properties of hepatocellular carcinoma via PI3K/Akt-PAK1 signal pathway

Research Article

The effects of p53 Arg72Pro polymorphism on glioma susceptibility: a meta-analysis

Research Article

Lack of association between interleukin-4 −524C>T polymorphism and colorectal cancer susceptibility

Research Article

RETRACTED ARTICLE: Steroid receptor co-activator-3 promotes osteosarcoma progression through up-regulation of FoxM1
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits